Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW)
New Taipei City, TW
Based in New Taipei City, Taiwan, Chunghwa Chemical Synthesis & Biotech Co., Ltd., established in 1964 and previously known as China Chemical Synthesis Industry Co., Ltd., specializes in the development, production, and distribution of active pharmaceutical ingredients (APIs). The company's market reach includes Taiwan and the United States. Their API portfolio encompasses products designed for immunosuppression, oncology, and cardiovascular conditions, in addition to various peptide compounds. Moreover, they manufacture a wide array of bulk pharmaceutical substances for numerous therapeutic applications, including anti-anxiety agents, antidiabetics, laxatives, antifungals, antihistamines, antiseptics, antiulcerants, cardiovascular medications, skeletal muscle relaxants, hypolipidemics, antineoplastics, antihyperlipidemics, and immunosuppressants. Complementing its product offerings, Chunghwa Chemical Synthesis & Biotech delivers bespoke research and development as well as contract manufacturing services to both emerging drug developers and established generic pharmaceutical firms.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +10.00% | -2.06% | +35.05% | +38.00% | +52.10% | +54.90% | +29.52% | -59.19% | -34.79% | +15.88% | -39.86% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-40.3% Q1'26: +87.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-567.0% Q1'26: +1,161.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+10.2% Q1'26: -10.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-39.7% Q1'26: +22.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-8.7% ★ Q1'26: +7.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-27.1% ★ Q1'26: -1.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-6.29× Q1'26: 2.53× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.16B
est: 1.08B (+7.8%)
|
1.20B
est: 1.25B (-4.2%)
|
1.17B
est: 1.21B (-3.3%)
|
1.02B
est: 1.14B (-10.6%)
|
1.16B
est: 1.12B (+3.3%)
|
1.54B
est: 1.54B (0.0%)
|
1.93B
est: 1.97B (-1.7%)
|
2.12B
est: 2.11B (+0.4%)
|
2.09B
est: 1.51B (+38.4%)
|
1.35B
est: 2.32B (-41.9%)
|
804.88M
est: 1.27B (-36.5%)
|
1.41B
1.41B – 1.41B
+11.3% YoY
|
| EBITDA |
447.31M
est: 358.97M (+24.6%)
|
214.36M
est: 416.58M (-48.5%)
|
252.01M
est: 402.26M (-37.4%)
|
165.73M
est: 379.62M (-56.3%)
|
250.75M
est: 372.96M (-32.8%)
|
786.21M
est: 514.15M (+52.9%)
|
651.27M
est: 655.17M (-0.6%)
|
743.72M
est: 701.96M (+5.9%)
|
545.93M
est: 300.39M (+81.7%)
|
277.66M
est: 462.32M (-39.9%)
|
-128.19M
est: 252.48M (-150.8%)
|
280.98M
280.98M – 280.98M
+11.3% YoY
|
| EBIT |
99.52M
est: 256.92M (-61.3%)
|
98.13M
est: 298.15M (-67.1%)
|
78.14M
est: 287.90M (-72.9%)
|
251.12M
est: 271.69M (-7.6%)
|
154.36M
est: 266.93M (-42.2%)
|
655.05M
est: 367.98M (+78.0%)
|
500.93M
est: 468.91M (+6.8%)
|
593.02M
est: 502.39M (+18.0%)
|
352.93M
est: 111.63M (+216.2%)
|
78.51M
est: 171.80M (-54.3%)
|
-319.54M
est: 93.82M (-440.6%)
|
104.41M
104.41M – 104.41M
+11.3% YoY
|
| Net Income |
308.36M
est: 218.02M (+41.4%)
|
60.28M
est: 115.87M (-48.0%)
|
85.77M
est: 76.99M (+11.4%)
|
234.25M
est: 266.81M (-12.2%)
|
117.00M
est: 106.72M (+9.6%)
|
531.87M
est: 512.65M (+3.8%)
|
400.78M
est: 418.67M (-4.3%)
|
465.87M
est: 451.28M (+3.2%)
|
264.91M
est: 84.29M (+214.3%)
|
53.03M
est: 277.73M (-80.9%)
|
-243.85M
est: -83.32M (-192.7%)
|
25.00M
25.00M – 25.00M
+130.0% YoY
|
| SGA |
175.09M
est: 135.94M (+28.8%)
|
169.93M
est: 157.76M (+7.7%)
|
180.41M
est: 152.34M (+18.4%)
|
159.08M
est: 143.76M (+10.7%)
|
152.06M
est: 141.24M (+7.7%)
|
202.10M
est: 194.71M (+3.8%)
|
239.89M
est: 248.12M (-3.3%)
|
271.78M
est: 265.83M (+2.2%)
|
233.80M
est: 189.58M (+23.3%)
|
182.14M
est: 291.77M (-37.6%)
|
103.99M
est: 159.34M (-34.7%)
|
177.32M
177.32M – 177.32M
+11.3% YoY
|
| EPS |
3.98
est: 2.86 (+39.2%)
|
0.78
est: 1.52 (-48.7%)
|
1.11
est: 1.01 (+9.9%)
|
3.02
est: 3.50 (-13.7%)
|
1.51
est: 1.40 (+7.9%)
|
6.86
est: 6.73 (+2.0%)
|
5.17
est: 5.49 (-5.9%)
|
6.01
est: 5.92 (+1.5%)
|
3.42
est: 1.52 (+125.4%)
|
0.70
est: 5.00 (-86.0%)
|
-4.39
est: -1.50 (-192.7%)
|
0.45
0.45 – 0.45
+130.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Value ETF AVES | 0.00% | 16.7K | 0.36% |
| 2 | Avantis Responsible Emerging Markets Equity ETF AVSE | 0.00% | 1.2K | 0.33% |
| 3 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 116.4K | 0.33% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 40.8K | 0.39% |
| 5 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 25.1K | 0.28% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 15.6K | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chao-Sheng Hong | Chief Auditor | — | male |
| Guanjie Wang | Accounting Supervisor | — | — |
| Jun-Jie Liao | Manager of Human Resource Office | — | male |
| Kuan-Chieh Wang | Manager of Finance Department & Head of Corporate Governance | — | male |
| Qing-Peng Wei | General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1762.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
